Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
申请人:Aventis Pharma S.A.
公开号:EP1621536A1
公开(公告)日:2006-02-01
The invention relates to novel products of formula (I):
in which p = 0, 1 and 2;
A = aryl, heteroaryl, carbocycle or heterocycle;
X = single bond, -N(R6)-, -O-, -C(O)-, -S(O)n-, -N(R6)-C(O)-, -N(R6)-C(O)-N(R6')-, -N(R6)-C(S)-N(R6')-, -N(R6)-C(O)O-, -N(R6)-SO2-, -N(R6)-SO2-N(R6')-, -C(O)-N(R6)-, -SO2-NR6-, -C(O)O-;
L1 = alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, heteroarylene;
R1 = hydrogen, alkyl, alkenyl, alkynyl or cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; -SO2R9, -C(O)R9; -C(O)OR9,-C(O)NR10R11, -C(S)NR10R11,-SO2NR10R11;
R2 = hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, either R1 and R2 with N, or NR1R2 with L1 may form a saturated or unsaturated heterocycle possibly containing O, N, S;
R3 = hydrogen; halogen; alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylenedioxy, heterocycle, aryl and heteroaryl, all optionally substituted; S(O)n-alkyl; amino, alkylamino, dialkylamino, with dialkylamino optionally forming with N a cycle, all optionally substituted;
R4, R4' and R4''= hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, oxo; with two from among R4, R4' and R4'' possibly forming with C a ring possibly containing O, N or S;
L2 = single bond, alkylene, alkenylene, alkynylene, cycloalkylene, -O-, -NR17-, -C(O)-, SO2;
Y = N-heterocycle possibly containing O, N or S;
R5 = hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; all these radicals being optionally substituted,
these products being in all the isomeric forms and the salts, as medicinal products.
该发明涉及以下式(I)的新产品:
其中p = 0、1和2;
A = 芳基、杂芳基、碳环或杂环;
X = 单键、-N(R6)-、-O-、-C(O)-、-S(O)n-、-N(R6)-C(O)-、-N(R6)-C(O)-N(R6')-、-N(R6)-C(S)-N(R6')-、-N(R6)-C(O)O-、-N(R6)-SO2-、-N(R6)-SO2-N(R6')-、-C(O)-N(R6)-、-SO2-NR6-、-C(O)O-;
L1 = 烷基、烯烃基、炔烃基、环烷基、苯基、杂芳基;
R1 = 氢、烷基、烯基、炔基或环烷基、芳基、杂芳基、芳基烷基、杂芳基烷基;-SO2R9、-C(O)R9;-C(O)OR9、-C(O)NR10R11、-C(S)NR10R11、-SO2NR10R11;
R2 = 氢、烷基、烯基、炔基、环烷基,或R1和R2中的任一者与N结合,或NR1R2与L1结合,可能形成含有O、N、S的饱和或不饱和杂环;
R3 = 氢;卤素;烷基、烯基、炔基、环烷基、烷氧基、烷二氧基、杂环、芳基和杂芳基,均可选择性取代;S(O)n-烷基;氨基、烷基氨基、二烷基氨基,其中二烷基氨基可选择性与N形成环,均可选择性取代;
R4、R4'和R4''= 氢、卤素、烷基、烯基、炔基、环烷基、芳基、杂芳基、氧代基;其中R4、R4'和R4''中的两个可能与C形成可能含有O、N或S的环;
L2 = 单键、烷基、烯基、炔基、环烷基、-O-、-NR17-、-C(O)-、SO2;
Y = 可能含有O、N或S的N-杂环;
R5 = 氢、卤素、烷基、烯基、炔基、环烷基、芳基、芳基烷基、杂芳基、杂芳基烷基;所有这些基团均可选择性取代,这些产品以所有同分异构体形式和盐形式存在,作为药用产品。